Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation (IBS-C) (ie, Fulfill Rome III Criteria for Child/Adolescent IBS and Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2024
Price :
$35
*
At a glance
- Drugs Linaclotide (Primary)
- Indications Constipation; Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors Allergan; Forest Laboratories
- 01 Mar 2024 Results published in the Journal of Pediatric Gastroenterology and Nutrition
- 13 Oct 2020 Results presented at the 28th United European Gastroenterology Week
- 12 Sep 2019 Status changed from recruiting to discontinued.